Nihar Ranjan Dash

Nihar Ranjan Dash

Auto-generated profile, based on publicly available information

Nihar Ranjan Dash

Department of Gastrointestinal Surgery and Liver Transplant, All India Institute of Medical Sciences, New Delhi, India

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2019 in European Journal of Cancer
Verified
Journal Article
Closed access
ASAtul Sharma
Atul Sharma
BMBIDHU K MOHANTI
BIDHU K MOHANTI
SCSurendra Pal Chaudhary
Surendra Pal Chaudhary
VSV. Sreenivas
V. Sreenivas
RSRanjit Kumar Sahoo
Ranjit Kumar Sahoo
VRVinod Raina
Vinod Raina

2 April 2018 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
UAUmang Arora
Umang Arora
SKSaurabh Kedia
Saurabh Kedia
PGPrerna Garg
Prerna Garg
SBSawan Bopanna
Sawan Bopanna
SJSaransh Jain
Saransh Jain
VAVineet Ahuja
Vineet Ahuja

14 August 2024 in International Journal of Surgery
Verified
Journal Article
Open access
SASupriya Mtech Awasthi
Supriya Mtech Awasthi
RKRahul Kumar
Rahul Kumar
DPDibyabhaba Pradhan
Dibyabhaba Pradhan
NRNeetu Rawal
Neetu Rawal
Harsh GoelHarsh Goel
Harsh Goel
PTPRANAY TANWAR
PRANAY TANWAR
Background: Gallbladder cancer (GBC) is a common gastrointestinal malignancy noted for its aggressive characteristics and poor prognosis, which is mostly caused by delayed detection. However, the scarcity of information regarding somatic mutations in Indian patients with GBC has hampered the development of efficient therapeutic options. In the present study, the authors attempted to bridge this gap by revealing the mutational profile of GBC. Materials and methods: To evaluate the somatic mutation profile, whole exome sequencing (WES) was performed on 66 tumor and matched blood samples from individuals with GBC. Somatic variant calling was performed using GATK pipeline. Variants were annotated at pathogenic and oncogenic levels, using ANNOVAR, VEP tools and the OncoKB database. Mutational signature analysis, oncogenic pathway analysis and cancer driver genes identification were performed at the functional level by using the maftools package. Results: Our findings focused on the eight most altered genes with pathogenic and oncogenic mutations: TP53, SMAD4, ERBB3, KRAS, ARID1A, PIK3CA, RB1, and AXIN1. Genes with pathogenic single nucleotide variations (SNVs) were enriched in oncogenic signaling pathways, particularly RTK-RAS, WNT, and TP53 pathways. Furthermore, our research related certain mutational signatures, such as cosmic 1, cosmic 6, and cosmic 18, 29, to known characteristics including patient age and tobacco smoking, providing important insights into disease etiology. Conclusions: Given the scarcity of exome-based sequencing studies focusing on the Indian population, this study represents a significant step forward in providing a framework for additional in-depth mutational analysis. Genes with substantial oncogenic and pathogenic mutations are promising candidates for developing targeted mutation panels, particularly for GBC detection.

31 October 2023 in Intestinal Research
Verified
Journal Article
Open access
PDF file
PKPeeyush Kumar
Peeyush Kumar
SVSudheer Kumar Vuyyuru
Sudheer Kumar Vuyyuru
PDPrasenjit Das
Prasenjit Das
BKBhaskar Kante
Bhaskar Kante
MRMukesh Kumar Ranjan
Mukesh Kumar Ranjan
VAVineet Ahuja
Vineet Ahuja
Background/Aims: Evidence on predictors of primary nonresponse (PNR), and secondary loss of response (SLR) to anti-tumor necrosis factor (anti-TNF) agents in inflammatory bowel disease is scarce from Asia. We evaluated clinical/biochemical/molecular markers of PNR/SLR in ulcerative colitis (UC) and Crohn’s disease (CD).Methods: Inflammatory bowel disease patients treated with anti-TNF agents (January 2005–October 2020) were ambispectively included. Data concerning clinical and biochemical predictors was retrieved from a prospectively maintained database. Immunohistochemistry for expression of oncostatin M (OSM), OSM receptor (OSM-R), and interleukin-7 receptor (IL-7R) were done on pre anti-TNF initiation mucosal biopsies.Results: One-hundred eighty-six patients (118 CD, 68 UC: mean age, 34.1±13.7 years; median disease duration at anti-TNF initiation, 60 months; interquartile range, 28–100.5 months) were included. PNR was seen in 17% and 26.5% and SLR in 47% and 28% CD and UC patients, respectively. In CD, predictors of PNR were low albumin (P<0.001), postoperative recurrence (P=0.001) and high IL-7R expression (P<0.027) on univariate; and low albumin alone (hazard ratio [HR], 0.09; 95% confidence interval [CI], 0.03–0.28; P<0.001) on multivariate analysis respectively. Low albumin (HR, 0.31; 95% CI, 0.15–0.62; P=0.001) also predicted SLR. In UC, predictors of PNR were low albumin (P<0.001), and high C-reactive protein (P<0.001), OSM (P<0.04) and OSM-R (P=0.07) stromal expression on univariate; and low albumin alone (HR, 0.11; 95% CI, 0.03–0.39; P=0.001) on multivariate analysis respectively. Conclusions: Low serum albumin at baseline significantly predicted PNR in UC and PNR/SLR in CD patients. Mucosal markers of PNR were high stromal OSM/OSM-R in UC and high IL-7R in CD patients.

14 May 2024 in Stem Cell Research & Therapy
Verified
Journal Article
Open access
PDF file
SSShekhar Swaroop
Shekhar Swaroop
SVSudheer Kumar Vuyyuru
Sudheer Kumar Vuyyuru
BKBhaskar Kante
Bhaskar Kante
PKPeeyush Kumar
Peeyush Kumar
SMSandeep Kumar Mundhra
Sandeep Kumar Mundhra
VAVineet Ahuja
Vineet Ahuja
Background: Perianal fistulas (PF) affect one-third patients with Crohn’s disease (CD) with limited therapeutic options. There is dearth of literature on safety and efficacy of bone marrow-derived mesenchymal stromal cells (BMSCs) in this population. Methods: An open-label, phase I/II, single-arm study was conducted involving local administration of human allogeneic bone marrow-derived mesenchymal stromal cells in perianal fistula of patients with Crohn’s disease refractory to standard therapies. Clinical severity and biomarkers were assessed at baseline and periodically until week 104 , and MRI at week 24 and 104. Primary and secondary objectives were to assess safety and efficacy respectively. Fistula remission was complete closure of fistula openings with < 2 cm perianal collection on MRI, and fistula response was decrease in drainage by ≥ 50%. Change in perianal disease activity index, quality-of-life and Van Assche index on MRI over time was assessed using mixed-effect linear regression model. Results: Ten patients (male:8, mean age:27.4 ± 12.0years) were recruited. Self-resolving procedure-related adverse events occurred in three patients, with no follow-up adverse events. In intention to treat analysis at week 24, two patients (20%) achieved fistula remission and seven (70%) had fistula response. At week 52, two (20%) patients were in remission and seven (70%) maintained response. At 104 weeks, two (20%) patients maintained response and one (10%) was in remission. Statistically significant decrease in perianal disease activity index (P = 0.008), Van Assche Index (P = 0.008) and improvement in quality-of-life (P = 0.001) were observed over time. Conclusions: Allogeneic BMSCs are safe and effective for the treatment of perianal fistulizing CD with significant improvement in clinical severity and radiological healing. Trial registration: The study was prospectively registered on Clinical trials registry – India (CTRI), CTRI/2020/01/022743 on 14 January 2020, http://ctri.nic.in.

2 July 2024 in Journal of Gastrointestinal Cancer
Verified
Journal Article
Closed access
PDF file
LALokesh Agarwal
Lokesh Agarwal
NDNihar Ranjan Dash
Nihar Ranjan Dash
SPSujoy Pal
Sujoy Pal
KMKumble Seetharama Madhusudhan
Kumble Seetharama Madhusudhan
VMVignesh Mani
Vignesh Mani